Nathanael Green’s practice bridges his scientific background with his legal training to focus on developing, protecting and leveraging his clients’ intellectual property. Nate counsels clients on portfolio management and protection strategies using both offensive and defensive considerations. Nate has experience with technologies across the life science space, including biologics, small molecules, diagnostic assays, AI-enabled biotechnologies, medical devices, organic chemistry and drug screening.
Before attending law school, Nate earned his PhD in Pharmacology from Baylor College of Medicine, where he conducted research on the intersection of RNA methylation and metabolism in renal cell carcinoma. Nate performed his research in MD Anderson Cancer Center’s Section of Nephrology, where he developed experience utilizing molecular biology techniques in a variety of disease models including cancer and diabetes. He now assists clients with patent portfolio management, patent prosecution, USPTO proceedings including examiner interviews and appeals, patentability analyses, IP strategy development, competitor portfolio monitoring, freedom to operate analyses, due diligence and collaboration with foreign associates for worldwide patent filings.
Representative experience
Experience with therapeutic technologies, including drafting and prosecuting patent applications directed to cell therapies, gene therapies, protein therapies, antibodies, protein–drug conjugates, therapeutic nucleic acids, viral therapies, biotherapeutics, small molecules and formulations thereof across therapeutic areas such as cancer, autoimmune, allergic and neurological diseases.
Experience with diagnostic, biomarker and AI-enabled personalized medicine technologies, including drafting and prosecuting patent applications directed to detecting and measuring biomarkers, such as proteins, miRNAs, lipids, SNPs, post-translational modifications and DNA and RNA methylation marks, to inform treatment strategies across diseases including cancer and liver disease. This experience includes work with research and analytical technologies, including drafting and prosecuting patent applications directed to nucleic acid sequencing methods (including detection of methylation and other base modifications), barcoding and library preparation strategies for DNA and RNA sequencing, antibody‑based research tools and antibody–detection fusions, proteomics approaches for detecting post‑translational modifications, proximity‑based and activity‑based chemical probe assays and computational chemistry and biology methods for structure–activity relationship analysis and gene expression profiling.
Experience with due diligence, including analyzing the strengths and weaknesses of intellectual property portfolios for potential investment, including for cancer-related and medical device technologies.
Education
-
JD, magna cum laude, University of Houston Law Center, 2022
- Houston Journal of International Law - Editor in Chief
- Moot Court
-
PhD, Pharmacology, Baylor College of Medicine, 2019
-
BS, magna cum laude, Pharmaceutical Chemistry and Biochemistry and Molecular Biology, Michigan Technological University, 2014
Admissions
- Texas State Bar
- US Patent and Trademark Attorney
Publications
- Co- author, "MTHFD2 links RNA methylation to metabolic reprogramming in renal cell carcinoma/Oncogene," Oncogene, 2019